ABCL vs MRK
AbCellera Biologics Inc. vs Merck & Co. — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
66
Buy
VS
| Metric | ABCL | MRK |
|---|
| AI Score |
66
|
70
|
| Price |
$9.75
|
$130.34
|
| P/E Ratio |
-18.07×
|
103.53×
|
| ROE |
-15.1%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
75.4%
|
| Debt / Equity |
0.15×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
90.0
|
64.5
|
| Beta |
1.191
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ABCL versus MRK.
MRK leads by 4 points.
MRK scores 70/100 (Buy) versus ABCL at 66/100 (Buy).
ABCL Committee View
67% agreement
6 analysts
The primary driver is revenue growing 101.3% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 77.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 90 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical